Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)
| dc.rights.license | open | en_US |
| dc.contributor.author | BARRE, Tangui | |
| dc.contributor.author | ROJAS ROJAS, Teresa | |
| dc.contributor.author | LACOMBE, Karine | |
| dc.contributor.author | PROTOPOPESCU, Camelia | |
| dc.contributor.author | POIZOT-MARTIN, Isabelle | |
| dc.contributor.author | NISHIMWE, Marie | |
| dc.contributor.author | ZUCMAN, David | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ESTERLE, Laure | |
| dc.contributor.author | BILLAUD, Eric | |
| dc.contributor.author | AUMAITRE, Hugues | |
| dc.contributor.author | BOUCHAUD, Olivier | |
| dc.contributor.author | REY, David | |
| dc.contributor.author | PIROTH, Lionel | |
| dc.contributor.author | SALMON-CERON, Dominique | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| dc.contributor.author | SOGNI, Philippe | |
| dc.contributor.author | CARRIERI, Maria Patrizia | |
| dc.contributor.author | SERFATY, Lawrence | |
| dc.contributor.author | MARCELLIN, Fabienne | |
| dc.date.accessioned | 2021-03-30T13:04:29Z | |
| dc.date.available | 2021-03-30T13:04:29Z | |
| dc.date.issued | 2021-02-04 | |
| dc.identifier.issn | 1478-7210 | en_US |
| dc.identifier.uri | oai:crossref.org:10.1080/14787210.2021.1884545 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26832 | |
| dc.description.abstractEn | Background: Cannabis use and elevated fatty liver index (FLI≥ 60) (a biomarker of hepatic steatosis in the general population) have been identified as predictors of HCV-related and overall mortality, respectively, in HIV-HCV co-infected patients. However, the relationship between cannabis use and the risk of elevated FLI has never been explored. Methods: Using five-year follow-up data from 997 HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort), we analyzed the relationship between cannabis use and FLI using mixed-effects multivariable logistic (outcome: elevated FLI yes/no) and linear (outcome: continuous FLI) regression models. Results: At the last follow-up visit, 27.4% of patients reported regular or daily cannabis use and 27.8% had elevated FLI. After multivariable adjustment, regular or daily cannabis use was associated with a 55% lower risk of elevated FLI (adjusted odds ratio [95% confidence interval]: 0.45 [0.22; 0.94]; p = 0.033) and lower FLI values (adjusted model coefficient: -4.24 [-6.57; -1.91], p<0.0001). Conclusions: Cannabis use is associated with a reduced risk of elevated fatty liver index in HIV-HCV co-infected patients. Further research is needed to confirm whether and how cannabinoids may inhibit the development of hepatic steatosis or other metabolic disorders in high-risk populations. | |
| dc.language.iso | EN | en_US |
| dc.source | crossref | |
| dc.subject.en | Cannabis | |
| dc.subject.en | Hepatitis C | |
| dc.subject.en | Chronic | |
| dc.subject.en | Human immunodeficiency virus | |
| dc.subject.en | Fatty liver | |
| dc.subject.en | Metabolic diseases | |
| dc.title.en | Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH) | |
| dc.title.alternative | Expert Rev Anti Infect Ther | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1080/14787210.2021.1884545 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33538612 | en_US |
| bordeaux.journal | Expert Review of Anti-infective Therapy | en_US |
| bordeaux.page | 1-10 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Recherches sur le Sida et les Hépatites Virales | en_US |
| bordeaux.import.source | dissemin | |
| hal.identifier | hal-03185691 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-03-30T13:04:33Z | |
| hal.export | true | |
| workflow.import.source | dissemin | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Review%20of%20Anti-infective%20Therapy&rft.date=2021-02-04&rft.spage=1-10&rft.epage=1-10&rft.eissn=1478-7210&rft.issn=1478-7210&rft.au=BARRE,%20Tangui&ROJAS%20ROJAS,%20Teresa&LACOMBE,%20Karine&PROTOPOPESCU,%20Camelia&POIZOT-MARTIN,%20Isabelle&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||